Your email has been successfully added to our mailing list.

×
0.00617283950617286 0.00646678424456199 0.00646678424456199 0.00690770135214578 0.00734861845972957 0.0088183421516754 0.00852439741328628 0.0088183421516754
Stock impact report

BRIEF-Roche: FDA Grants Priority Review To Genentech’S Polatuzumab Vedotin [Reuters]

ROCHE HOLDING LTD S/ADR (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
Company Research Source: Reuters
BRIEF-Roche: FDA Grants Priority Review To Genentech’S Polatuzumab Vedotin | Reuters 1 Min Read Feb 19 (Reuters) - Roche Holding AG: * FDA GRANTS PRIORITY REVIEW TO GENENTECH’S POLATUZUMAB VEDOTIN IN PREVIOUSLY TREATED AGGRESSIVE LYMPHOMA * GENETECH TODAY ANNOUNCED THAT U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED COMPANY’S BIOLOGICS LICENSE APPLICATION (BLA) AND GRANTED PRIORITY REVIEW FOR POLATUZUMAB VEDOTIN IN COMBINATION WITH BENDAMUSTINE PLUS RITUXAN(® )(RITUXIMAB) (BR) FOR TREATMENT OF PEOPLE WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL * FDA IS EXPECTED TO MAKE A DECISION ON APPROVAL BY AUGUST 19, 2019 Source text for Eikon: Further company coverage: (Berlin Speed Desk) All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2019 Reuters. All Rights Reserved. BRIEF-Roche: FDA Grants Priority Review To Genentech’S Polatuzumab Vedotin Feb 19 (Reuters) - Roche Holding AG: * FDA GRANTS PRIORITY R Show less Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RHHBY alerts
Opt-in for
RHHBY alerts

from News Quantified
Opt-in for
RHHBY alerts

from News Quantified